LYBALVI
Live / Registered — Registered (as of 20 Jul 2021)
What this means for you
Registered since 20 Jul 2021. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (the §8 declaration of use is due by 20 Jul 2027, and its filing window is open now).
Record
- Serial number
- 87700839
- Registration number
- 6428572
- Mark type
- Word mark
- Filed
- 29 Nov 2017
- Published for opposition
- 24 Apr 2018
- Registered
- 20 Jul 2021
- Next maintenance filing
- §8 declaration of use, due by 20 Jul 2027 (grace period to 20 Jan 2028)
- Attorney of record
- Norm J. Rich
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of psychiatric and neurodegenerative diseases and disorders including schizophrenia, depression, major depressive disorder, stress, anxiety, treatment resistant depression, bipolar depression, bipolar disorder; pharmaceutical preparations for the mitigation of weight gain and the treatment of metabolic diseases and dyslipidemia
Owner
- Alkermes Pharma Ireland Limited, Dublin, IE
- Alkermes Pharma Ireland Limited, Dublin, IE
- Alkermes Pharma Ireland Limited, Dublin, IE
Prosecution history
- 20 Jul 2026 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
- 24 Apr 2026 — ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
- 20 Jul 2021 — REGISTERED-PRINCIPAL REGISTER
- 17 Jun 2021 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 16 Jun 2021 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 17 May 2021 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 17 May 2021 — NON-FINAL ACTION E-MAILED
- 17 May 2021 — SU - NON-FINAL ACTION - WRITTEN
- 26 Apr 2021 — STATEMENT OF USE PROCESSING COMPLETE
- 22 Apr 2021 — USE AMENDMENT FILED
- 22 Apr 2021 — TEAS STATEMENT OF USE RECEIVED
- 10 Nov 2020 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 09 Nov 2020 — SOU EXTENSION 5 GRANTED
- 29 Oct 2020 — SOU EXTENSION 5 FILED
- 09 Nov 2020 — CASE ASSIGNED TO INTENT TO USE PARALEGAL